Allergic sensitization is a risk factor in the development of acute asthma exacerbations with viral respiratory infections. Heymann et al 1 demonstrated that allergic sensitization and increased serum IgE levels to house dust mite enhance the likelihood that a rhinovirus respiratory tract infection will cause an asthma exacerbation. Furthermore, allergen exposure in allergic patients increases the risk for respiratory virus-induced wheezing and asthma exacerbations. 2, 3 A critical link between IgE levels and suppression of Toll-like receptor (TLR) 9-induced plasmacytoid dendritic cell (pDC) IFNa responses was first described by Schroeder et al, 4 suggesting that pDC antiviral responses might be suppressed similarly in the setting of atopy. We observed that the magnitude of pDC IFN-a responses to ex vivo viral challenge is inversely related to serum IgE levels. 5 In addition, we showed that stimulation of the IgE/FcεRI pathway in pDCs through IgE cross-linking abrogates viral and TLR7-induced pDC IFN-a production, 5, 6 a finding that could explain why pDCs isolated from patients with allergic asthma have impaired IFN-a responses to viruses. Furthermore, surface expression of FcεRI on pDCs significantly correlates with serum IgE concentrations 7 and is associated with diminished virusinduced IFN-a responses in these cells. 5 Reduction of IgE levels with omalizumab can significantly reduce pDC FcεRI expression, 8, 9 a finding that could translate to improved antiviral responses in these cells. Collectively, these data suggest a significant interaction between IgE level, FcεRI expression, and asthma exacerbations and also that reducing IgE and FcεRI expression in vivo could restore IFN-a responses and possibly contribute to the prevention of virus-provoked asthma exacerbations.
The Preventative Omalizumab or
Step-up Therapy for Severe Fall Exacerbations (PROSE) study (clincaltrials.gov no. NCT01430403) was designed to evaluate the effect of reducing IgE levels with omalizumab in vivo on asthma exacerbations, as well as on ex vivo pDC antiviral IFN-a responses. Children treated with omalizumab had a significant restoration of ex vivo IFN-a responses in PBMCs, and the group with a greater restoration in IFN-a responses had a lower asthma exacerbation rate. 10 In this report we tested the hypothesis that omalizumab treatment would (1) boost antiviral IFN-a responses of both PBMCs and purified pDCs in the presence and absence of IgE cross-linking and (2) attenuate pDC FcεRIa expression. We also investigated whether these omalizumab-induced cellular changes were associated with clinical outcomes. Finally, we used multivariate modeling to determine whether the cellular phenotypes and IFN-a responses in our study would improve the predictive value of a previously developed model for asthma exacerbations in this population of high-risk children.
METHODS

Mechanistic study design
In participants from 2 of the 8 sites of the PROSE clinical trial (UT Southwestern Medical Center, Dallas, Texas, and National Jewish Health, Denver, Colorado), blood for ex vivo assays was drawn before randomization and 12 to 16 weeks after initiation of treatment. These assays were designed to measure the effect of IgE cross-linking on virus (rhinovirus and influenza)-induced and TLR7 agonist (gardiquimod)-induced IFN-a in cultures of PBMCs (all participants) and pDCs (in a subset of participants) and to determine the effect of omalizumab versus placebo treatment on these IFN-a responses.
Isolation of PBMCs, pDCs, culture conditions, and reagents
PBMCs were isolated by means of density centrifugation with Ficoll-Paque (GE Healthcare, Fairfield, Conn). In a subset of participants, pDCs were purified from PBMCs by means of negative selection with antibody-coated magnetic particles ( 
Flow cytometry
PBMCs were stained 5 with the following fluorochrome-conjugated antihuman antibodies: HLA-DR allophycocyanin (APC)-Cy7, lineage-fluorescein isothiocyanate (FITC) mixture, CD14-Pacific Blue, CD123-PeCy5 (BD Biosciences), and FcεRIa-PE (eBioscience, San Diego, Calif); acquired on a BD LSR II flow cytometer (BD Biosciences); and analyzed by using FlowJo software (TreeStar, Ashland, Ore). pDCs were identified as lineagenegative, HLA-DR 1 , and CD123 1 cells. The mean fluorescence intensity of FcεRIa was determined by using flow cytometry and subsequently converted to molecules of equivalent soluble fluorochrome by using the Ultra Rainbow Calibration Kit (BD Biosciences).
IFN-a quantification
IFN-a levels were measured by using the Human IFN-a (panspecific to detect 12 IFN-a subtypes) ELISA Kit (MabTech, Cincinnati, Ohio) and analyzed on an ELISA reader DTX 880 Multimode detector (Beckman Coulter, Fullerton, Calif).
RNA isolation and qRT-PCR for detection of FcεRIa and mRNA of interferon signaling and response genes
Total pDC RNA was extracted from 2 3 10 4 pDCs by using RNA-Bee (TelTest, Friendswood, Tex) and chloroform, as previously described, and stored at 2808C. 5 Total PBMC RNA was extracted from 1.5 to 2 3 10 6 PBMCs with the Qiagen RNeasy Mini Kit (Qiagen, Valencia, Calif). cDNA synthesis was carried with a High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems, Foster City, Calif). Expression of TLR7 and FCER1A mRNA in unstimulated pDCs and PBMCs and FCER1G mRNA in unstimulated PBMCs was quantified by performing quantitative RT-PCR with the CFX384 Real Time system (BioRad Laboratories, Hercules, Calif). TLR7, IFNB1, IFNA1, IFIT1, interferon regulatory factor 7 (IRF7), and DDX58 expression was also measured in cultured PBMCs. Sequences for TLR7 and FcεRIa probes/primers (TaqMan) shown in Table E1 in this article's Online Repository at www.jacionline.org were used, as previously reported. 5 The reporter dye and quencher were 6-fluorescein amidite and tetramethylrhodamine, respectively. Applied Biosystems TaqMan Assays (Thermo Fisher Scientific, Waltham, Mass) shown in Table E2 in this article's Online Repository at www.jacionline.org were used for IRF7, IFNB1, IFNA1, DDX58, and IFIT1. mRNA expression for all genes in cultured PBMCs was normalized to hypoxanthine-guanine phosphoribosyltransferase mRNA (Thermo Fisher Scientific). mRNA expression for all genes in unstimulated PBMCs and pDCs was normalized to hypoxanthine-guanine phosphoribosyltransferase mRNA or PPIA mRNA (Thermo Fischer Scientific). Results were based on 2 2DDct values.
Statistical analysis
Cell values were skewed and therefore log-transformed for statistical tests and models. To compare differences between prerandomization and postrandomization within treatment groups (placebo and omalizumab), paired t tests were used, and ratio of geometric means were reported. Change between prerandomization and postrandomization was calculated by using a log difference. Change was dichotomized at the median value to compare exacerbation rates by the level of prerandomization versus postrandomization change. Logistic regression was performed (Firth method was used in the case of zero counts) by using dichotomized change as the predictor and any exacerbation as the outcome; associated odds ratios were reported. Pearson correlations were used to compare continuous change between variables.
Because of the larger sample size required for multivariate modeling of exacerbations, participants from the third arm of the PROSE clinical trial, an arm that received an inhaled corticosteroid boost, were pooled together with placebo-treated participants. Notably, the primary outcome in the inhaled corticosteroid arm did not differ from placebo in the PROSE trial. 10 The multivariate modeling process consisted of 3 steps. First, prerandomization mechanistic variables were compared between exacerbators and nonexacerbators by using t tests within treatment group (non-omalizumab and omalizumab). Because of the exploratory nature of the analysis, we did not account for multiple comparisons. Next, an elastic net procedure was performed to select the most relevant baseline mechanistic outcomes after adjusting for known baseline predictors of exacerbations. 12 Finally, logistic models were fit by using known baseline predictors of exacerbations (age, total IgE, atopy, blood eosinophils, exacerbations in the previous 90 days, FEV 1 /forced vital capacity ratio, and treatment step) 13 stratified by treatment group. Similar models were fit by using the known predictors of exacerbations and the PBMC mechanistic outcomes selected by using the elastic net procedure.
14 All cellular phenotype and IFN-a response variables with less than 40% missing data were included as candidate predictors. Before multivariate modeling, any missing data among the candidate predictors (which amounted to 5% of the values) were imputed by using an imputation based on a random forest approach. Nested models were compared by using likelihood ratio tests and area under the receiver operating characteristic curve. SAS 9.3 (SAS Institute, Cary, NC) and R version 3.3.2 software were used for analyses.
RESULTS
IFN-a responses were evaluated in participants receiving omalizumab and placebo treatment (n 5 92) at 2 clinical sites. Participants had similar demographic and laboratory characteristics as those in the multisite clinical trial, including low income, predominant Hispanic ethnicity, increased peripheral blood eosinophil counts, and total serum IgE levels (see Table E3 in this article's Online Repository at www.jacionline.org). No significant differences in baseline characteristics were found between subjects from the 2 sites (data not shown).
Effect of omalizumab treatment on ex vivo antiviral IFN-a responses in PBMCs and purified pDCs
Ex vivo antiviral IFN-a responses were first measured in PBMC cultures (n 5 92) obtained at 2 time points in the study: before randomization and 12 to 16 weeks after treatment was initiated. As previously reported, PBMC generation of IFN-a to rhinovirus in the presence of IgE cross-linking was significantly increased in the postomalizumab treatment group compared with the posttreatment placebo group. 10 We now report that omalizumab treatment significantly increased IFN-a responses after IgE cross-linking and stimulation with either rhinovirus (ratio of geometric means, 2.06; 95% CI, 1.20-3.55; P 5 .01) or influenza virus (ratio of geometric means, 1.57; 95% CI, 1.09-2.25; P 5 .02; Fig 1 and Table I ). In contrast, omalizumab treatment did not significantly affect IFN-a responses to rhinovirus, influenza virus, or gardiquimod in the absence of ex vivo IgE crosslinking.
pDCs were purified from a subset of participants (n 5 43) to determine whether omalizumab affected pDC antiviral IFN-a responses. Similar to effects noted with PMBCs, omalizumab significantly enhanced rhinovirus-induced IFN-a responses of purified pDCs in the presence of IgE cross-linking treatment ( Fig  1 and Table I ; ratio of geometric means, 4.15; 95% CI, 1.76-9.77; P 5 .003). In contrast, omalizumab treatment had no significant effects on pDC-secreted IFN-a responses in the absence of IgE cross-linking. Because of the low frequency of pDCs in blood samples, insufficient numbers of pDCs were available to evaluate influenza virus-or gardiquimod-stimulated pDC IFN-a responses in the presence of IgE cross-linking.
We reported previously that the risk for asthma exacerbation after omalizumab treatment was related to restoration of rhinovirus-induced IFN-a responses of PBMCs. 10 Here we investigated whether omalizumab's effects on IFN-a responses, as induced by other ex vivo stimulation conditions in PBMCs or pDCs, had a similar relationship to asthma exacerbations (see Table E4 in this article's Online Repository at www.jacionline. org). We found no additional significant relationships between IFN-a restoration and proportions of exacerbations.
Effect of omalizumab on TLR7 mRNA expression in unstimulated PBMCs and pDCs TLR7, a sensor of single-stranded viral RNA, plays an important role in virus-induced pDC IFN-a secretion, 15, 16 and IgE cross-linking has been shown to impair virus-induced TLR7 expression. 15 We hypothesized that omalizumab can induce TLR7 expression and that this effect could contribute to observed increases in IFN-a responses. Unexpectedly, treatment with omalizumab resulted in decreased expression of TLR7 mRNA in unstimulated PMBCs (P 5 .002) and pDCs (P 5 .008), as shown in Table II . In addition, there were nonsignificant trends for lower exacerbation rates in the group with the greatest omalizumab-associated change/decrease in PBMC and pDC TLR7 expression (see Table E5 in this article's Online Repository at www.jacionline.org). Omalizumab did not affect baseline PBMC expression of IRF7, a master regulator of pDC IFN-a secretion (data not shown). 17 
Effect of omalizumab on transcription of genes related to IFN-a responses
We next tested the hypothesis that omalizumab was associated with upregulation of other genes involved in type I interferon signaling, including TLR7; IRF7
17
; IFNB1, the first member of the type I interferon (IFN-a/b) family to be secreted; IFNA1, one of at least 12 distinct IFN-a subtypes 18 ; IFIT1, an interferon-stimulated gene 18 ; and DDX58 (retinoic acid-inducible gene I [RIG-I]), a cytoplasmic sensor of pathogenassociated molecular patterns within viral RNA. Cells obtained before and during omalizumab treatment were stimulated with rhinovirus and IgE cross-linking. Omalizumab significantly increased transcription of IFNB1 (ratio of geometric means, 1.95; 95% CI, 1.04-3.66; P 5 .04) and DDX58 (RIG-I; ratio of geometric means, 1.43; 95% CI, 1.03-1.99; P 5 .04) mRNA (Table III) . Transcription of TLR7, IRF7, IFNA1, and IFIT1 was not significantly affected.
Effects of omalizumab treatment on surface FcεRIa expression on pDCs
As previously demonstrated, 8 omalizumab treatment significantly reduced FcεRIa surface expression on pDCs (Fig 2, A, and Table IV) . We next tested whether omalizumab affected FcεRIa mRNA levels in either PBMCs or pDCs and found that this was not the case (Table IV) . Similarly, omalizumab treatment did not affect mRNA levels of the FcεRI receptor g chain (FcεRIg), a transmembrane adaptor of the FcεRI complex (data not shown). FCER1G mRNA expression was measured only in PBMCs because of the limited availability of pDC RNA.
We next tested whether omalizumab-induced reductions in pDC FcεRIa surface expression were related to increased rhinovirus-induced IFN-a secretion in the presence of IgE cross-linking and found a modest inverse correlation (Fig 2, B , left panel; Pearson correlation 5 20.26; P 5 .05). There was a similar trend in parallel studies with purified pDCs (Fig 2, B, right  panel) . Finally, among omalizumab-treated participants, a significant association between changes in pDC FcεRIa surface expression and exacerbation rate was observed (odds ratio, 0.17; 95% CI, 0.02-0.74; P 5 .02; Fig 2, C , and see Table E5 ).
Sample sizes for all of the mechanistic variables included in Tables I-IVand Figs 1 and 2 , A-C, are displayed in Table E6 in this article's Online Repository at www.jacionline.org by treatment group and asthma exacerbation status. Fig E1 in this article' s Online Repository at www.jacionline.org provides a visual representation of the overlap between participants with available mechanistic data and exacerbation status.
Prediction of asthma exacerbations
To investigate the association between mechanistic variables and exacerbations within treatment groups (omalizumab and nonomalizumab), we first explored univariate associations (see Table  E7 in this article's Online Repository at www.jacionline.org). Mechanistic variables assessed during the prerandomization period included PBMC IFN-a responses; unstimulated PBMC expression of FCER1A, TLR7, and IRF7 mRNA; and pDC surface FcεRIa expression. Only variables with less than 40% missing data were included. Two variables were identified as risk factors for exacerbations in the non-omalizumab group, including PBMC IRF7 mRNA after stimulation with rhinovirus and IgE cross-linking (ratio of geometric means exacerbators/nonexacerbators, 0.44; P 5.04) and FCER1A mRNA expression in unstimulated PBMCs (ratio of geometric means, 0.61; P 5 .03).
We next investigated whether addition of these baseline mechanistic measurements could improve an existing predictive model for asthma exacerbations. Using a multivariate model that includes clinical and laboratory parameters, 12, 13 we obtained a significant area under the curve (0.89 and 0.87 and P 5 .01 and .008 for the ''non-omalizumab'' group [combined placebo and inhaled corticosteroid boost] and the omalizumab group, respectively; model 1, Table V) .
Using the variable selection procedure, we next added mechanistic variables measured at prerandomization (baseline) to this model. In the non-omalizumab group baseline PBMC FCER1A mRNA expression was found to be a significant predictor of exacerbations after accounting for the set of clinical and laboratory parameters in model 1. In particular, addition of baseline PBMC FCER1A mRNA expression increased the area under the curve by 0.08 to 0.97 (P 5 .002) and reduced the proportions of falsepositive and false-negative predictions by 50% (see Table E8 in this article's Online Repository at www.jacionline.org). 19 No mechanistic parameters were found to be significant additions to known clinical predictors of exacerbations in the omalizumab group. 5, 6 and this represents a potential mechanism for more severe viral respiratory illnesses in patients with allergic asthma. We demonstrated previously that omalizumab treatment of urban children with moderate asthma restores ex vivo PBMC IFN-a responses and that these improved responses were related to a lower risk for asthma exacerbation. 10 In the present study we extend these findings by showing that omalizumab treatment in vivo restores IFN-a responses to both rhinovirus and influenza. Furthermore, we demonstrated omalizumab's effects on pDCs, including reduced expression of FcεRIa on the cell surface and increased virus-induced IFN-a responses in the presence of IgE cross-linking. These effects on pDCs, which are the major source of virus-induced IFN-a among immune cells, 20 were inversely correlated. Type I interferons suppress development and stability of T H 2 lymphocytes; increasing IFN-a levels could thus diminish T H 2-mediated allergic inflammation associated with asthma pathogenesis. 21 In support of this, inhaled IFN-b has shown promise as a potential treatment for virus-induced asthma exacerbations. 22 These findings provide additional insights into IgE-mediated mechanisms that suppress antiviral responses.
DISCUSSION
Overexpression of FcεRIa and cross-linking of this receptor can disrupt virus-induced IFN-a responses,
Our findings suggest that omalizumab improves IFN-a responses through reduction of FcεRIa, the a-chain of the high-affinity IgE receptor, on pDC surfaces. Elegant studies of pDC signaling performed by Cao et al 23, 24 suggest that the mechanism for this effect might involve FcεRIg, an immunoreceptor tyrosine-based activation motif-containing transmembrane adaptor of the FcεRI complex that can transduce inhibitory signals through pDC surface receptors ILT7 (immunoglobulinlike transcript 7) and BDCA-2 (blood dendritic cell antigen-2). FcεRIg signaling through these receptors inhibits TLR7/9-induced pDC interferon responses through a B-cell receptor-like pathway involving Lyn/BLK, Syk, and BLNK. 24 This immunoreceptor tyrosine-based activation motif-mediated inhibition of pDC interferon is effectively reversed by Syk inhibition in primary human pDCs 23 and by knockdown of Syk and FcεRIg in a pDC cell line 25 and is likely also involved in IgE-mediated inhibition of pDC IFN-a responses through FcεRIa-induced FcεRIg signaling. Therefore reduction of surface FcεRIa could diminish subsequent FcεRIg signaling in the presence of IgE cross-linking conditions and lead to increased capacity of pDCs to secrete IFN-a in an allergic environment, although we were unable to assess this in our study. The increased rhinovirus-induced PBMC IFNB1 and DDX58 (RIG-I) mRNA levels observed in the posttreatment omalizumab group suggest that pathways downstream of FcεRIg and upstream of IFN-a signaling might be affected. Although we observed no differences in IRF7 transcription in the posttreatment omalizumab group, it is possible that critical signaling events, such as IRF7 phosphorylation, which is required for IRF7 activation, nuclear translocation, and induction of type I interferon expression, could be enhanced in the setting of reduced IgE and FcεRIa. Other posttranslational modifications known to regulate IRF7, including ubiquitination, 26 could contribute similarly to the observed effects but were not assessed in our study. Because RIG-I (DDX58) signaling also promotes type I interferon production, 27 increased rhinovirusinduced RIG-I mRNA levels after omalizumab could also contribute to enhanced IFN-a responses. Proof of this concept would require demonstration of diminished FcεRIg signaling in pDCs from omalizumab-treated participants, which was not feasible given the limited numbers of pDCs available for these analyses. Investigating the effect of omalizumab on pDC FcεRIg signaling could be tested in future omalizumab treatment studies in adults, from whom higher blood volumes could be obtained.
The finding that omalizumab reduces pDC surface FcεRIa protein levels without regulating FcεRIa transcription suggests that this effect is likely related to reduction of free serum IgE levels. Consistent with this idea, free IgE levels have been shown to correlate with pDC surface FcεRIa expression both before and after omalizumab treatment. 9 The duration of reduced pDC FcεRIa expression after discontinuation of omalizumab was not measured in our study. Basophil surface FcεRIa protein expression has been shown to increase after omalizumab withdrawal in atopic subjects, paralleling the increase in free serum IgE levels. 19 Given that serum IgE similarly regulates surface FcεRIa protein expression on pDCs, it is reasonable to hypothesize that pDC FcεRIa levels would also increase after omalizumab withdrawal as free serum IgE levels increase to preomalizumab levels. Whether such a return to preomalizumab pDC FcεRIa protein expression levels would result in loss of the observed improved IFN-a responses also remains undetermined and represents an area for future investigation. In addition to FcεRIa-and FcεRIg-mediated effects, other mechanisms of allergic inflammation-induced inhibition of antiviral responses have been reported. Aeroallergen-induced IL-33 can suppress pDC IRF7 expression and impair IFN-a production and promote a respiratory virus-induced asthma phenotype in a murine model of asthma.
28 TLR7 hyporesponsiveness and reduced function have been reported in both murine and human studies of allergic disease [28] [29] [30] and likely contribute to associated defective IFN-a antiviral responses. Reduced rhinovirus-induced PBMC expression of other critical signaling molecules, including IRF1, IRF7, nuclear factor kB family members, and signal transducer and activator of transcription 1, have also been reported in patients with allergic asthma 30 and suggest roles for both interferon-dependent and independent pathways in the synergistic contributions of allergens and viruses to exacerbations of atopic asthma. In addition, the T H 2 cytokines IL-4 and IL-13 inhibit TLR3 expression and IRF3 activation, resulting in impaired rhinovirus-induced interferon responses in human bronchial epithelial cells. 31 The clinical relevance of omalizumab's effect on pDC surface FcεRIa expression is underscored by association of a lower exacerbation rate with omalizumab-induced change in FcεRIa surface protein expression. Based on this, one might expect that higher baseline FcεRIa expression would have predicted exacerbations in this population of high-risk children. Surprisingly, this was not the case; pDC surface FcεRIa expression did not improve the ability to predict exacerbations when added to an existing prediction model, which can be attributed to its high correlation with total IgE levels. In contrast, baseline FCER1A mRNA expression in unstimulated PBMCs significantly enhanced the accuracy of an existing predictive model of asthma exacerbations 12 in our study population, although this factor was not influenced by omalizumab treatment. The finding that mRNA levels for FcεRIa fit and improve this asthma exacerbation prediction model supports the concept that the high affinity IgE receptor plays an important role in exacerbations.
We have demonstrated that omalizumab therapy results in improved virus-induced pDC IFN-a responses and have linked omalizumab-induced changes in surface pDC FcεRIa expression to improved clinical outcomes (decreased asthma exacerbation rate). Our finding that FCER1A mRNA expression is not affected by omalizumab yet can be used to improve prediction of asthma exacerbations is intriguing and underscores the complexity of FcεRIa regulation in immune cells. 32 Future studies investigating the connection between virus-induced pDC IFN-a responses and FcεRIa regulation are needed to further define the mechanisms underlying the connection between atopy, antiviral response, and allergic disease. Our findings support the concept that targeting the IgE pathway in pDCs represents a promising strategy to increase interferon responses, improve antiviral activity in the airways, and reduce exacerbations of allergic asthma. FVC, Forced vital capacity; NA, no variables were selected by the feature selection algorithm; ROC, receiver operating characteristic. *The set of mechanistic variables considered by using the feature selection procedure included data obtained from unstimulated PMBCs (FcεRIa protein and mRNA expression and TLR7 and IRF7 mRNA expression) and from ex vivo rhinovirus-stimulated PBMC assays (IFN-a response) . The new mechanistic variables selected by using the feature selection procedure were then included in model 2.
Includes participants receiving placebo (n 5 23) and inhaled corticosteroid boost (n 5 36) treatments. àKnown clinical predictors include age, total IgE level, atopy, blood eosinophil count, exacerbations in previous 90 days, FEV 1 /forced vital capacity ratio, and treatment step. Scores on the Childhood Asthma Control Test (C-ACT) and Asthma Control Test (ACT) were measured on scales of 0 to 27 and 5 to 25, respectively. A score of 19 or less on either test indicates that asthma is not well controlled. The minimally important difference for ACT equals 3 points; for the C-ACT, a 3-point increase suggests a clinically relevant improvement in asthma control, whereas a 2-point decrease suggests a clinically relevant worsening. àThe number of days with symptoms was calculated as the largest of the following variables during the previous 2 weeks: number of days with wheezing, chest tightness, or cough; number of nights of sleep disturbance; and number of days when activities were affected. This symptom scale ranges from 0 to 14 days per 2-week period.
§Six treatment steps were established, which is consistent with report 3 of the National Asthma Education and Prevention Program guidelines to standardize prescribing patterns according to levels of asthma severity summarized here. Steps 1 and 2 apply to mild asthma, step 3 applies to moderate asthma, and steps 4 through 5 apply to severe asthma. At step 0, the recommendation is for no asthma control medication or albuterol as needed; at step 1, the recommendation is for 50 mg of fluticasone twice a day; at step 2, the recommendation is for 100 mg of fluticasone twice a day; at step 3, the recommendation is for 250 mg of fluticasone twice a day; at step 4, the recommendation is for 250 mg of fluticasone and 50 mg of salmeterol twice a day (Advair; GlaxoSmithKline, Research Triangle Park, NC); and at step 5, the recommendation is for 500 mg of fluticasone and 50 mg of salmeterol twice a day (Advair). ); FcεRIa was measured by using flow cytometry.
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